These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29578126)

  • 1. Efficacy and Safety of Different Bisphosphonates for Bone Loss Prevention in Kidney Transplant Recipients: A Network Meta-Analysis of Randomized Controlled Trials.
    Yang Y; Qiu S; Tang X; Li XR; Deng LH; Wei Q; Fu P
    Chin Med J (Engl); 2018 Apr; 131(7):818-828. PubMed ID: 29578126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of bisphosphonate and its supplements for bone loss in kidney transplant recipients: a systematic review and network meta-analysis.
    Yang Y; Qiu S; Deng L; Tang X; Li X; Wei Q; Fu P
    BMC Nephrol; 2018 Oct; 19(1):269. PubMed ID: 30340537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for steroid-induced osteoporosis.
    Allen CS; Yeung JH; Vandermeer B; Homik J
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD001347. PubMed ID: 27706804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials.
    Wang J; Yao M; Xu JH; Shu B; Wang YJ; Cui XJ
    Osteoporos Int; 2016 May; 27(5):1683-90. PubMed ID: 26733377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Bisphosphonates for Low Bone Mineral Density After Kidney Transplantation: A Meta-Analysis.
    Kan SL; Ning GZ; Chen LX; Zhou Y; Sun JC; Feng SQ
    Medicine (Baltimore); 2016 Feb; 95(5):e2679. PubMed ID: 26844505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment for osteoporosis in people with ß-thalassaemia.
    Bhardwaj A; Swe KM; Sinha NK; Osunkwo I
    Cochrane Database Syst Rev; 2016 Mar; 3():CD010429. PubMed ID: 26964506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for preventing bone disease in kidney transplant recipients.
    Palmer SC; McGregor DO; Strippoli GF
    Cochrane Database Syst Rev; 2007 Jul; (3):CD005015. PubMed ID: 17636784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates in multiple myeloma: an updated network meta-analysis.
    Mhaskar R; Kumar A; Miladinovic B; Djulbegovic B
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003188. PubMed ID: 29253322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials.
    Palmer SC; Strippoli GF; McGregor DO
    Am J Kidney Dis; 2005 Apr; 45(4):638-49. PubMed ID: 15806466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bisphosphonates on bone loss in the first year after renal transplantation--a meta-analysis of randomized controlled trials.
    Mitterbauer C; Schwarz C; Haas M; Oberbauer R
    Nephrol Dial Transplant; 2006 Aug; 21(8):2275-81. PubMed ID: 16574684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate use in children with cerebral palsy.
    Hurley T; Zareen Z; Stewart P; McDonnell C; McDonald D; Molloy E
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD012756. PubMed ID: 34224134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up.
    Tillmann FP; Schmitz M; Jäger M; Krauspe R; Rump LC
    Int Urol Nephrol; 2016 Feb; 48(2):279-86. PubMed ID: 26498632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of bisphosphonate therapy in kidney transplant recipients: a systematic review and meta-analysis.
    Toth-Manikowski SM; Francis JM; Gautam A; Gordon CE
    Clin Transplant; 2016 Sep; 30(9):1090-6. PubMed ID: 27327448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of calcium and vitamin D compounds on bone mineral density in patients undergoing glucocorticoid therapies: a network meta-analysis.
    Deng J; Silver Z; Huang E; Zheng E; Kavanagh K; Panicker J
    Clin Rheumatol; 2021 Feb; 40(2):725-734. PubMed ID: 32681366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates for osteoporosis in people with cystic fibrosis.
    Conwell LS; Chang AB
    Cochrane Database Syst Rev; 2009 Oct; (4):CD002010. PubMed ID: 19821288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and safety of pamidronate therapy on bone mass density in early post-renal transplant period: a meta-analysis of randomized controlled trials.
    Wang Z; Han Z; Tao J; Lu P; Liu X; Wang J; Wu B; Huang Z; Yin C; Tan R; Gu M
    PLoS One; 2014; 9(9):e108106. PubMed ID: 25265508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates for osteoporosis in people with cystic fibrosis.
    Conwell LS; Chang AB
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD002010. PubMed ID: 24627308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates for osteoporosis in people with cystic fibrosis.
    Conwell LS; Chang AB
    Cochrane Database Syst Rev; 2012 Apr; (4):CD002010. PubMed ID: 22513903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.